SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.

ABSTRACT:

Background

Schlafen 11 (SLFN11) has been linked with response to DNA-damaging agents (DDA) and PARP inhibitors. An in-depth understanding of several aspects of its role as a biomarker in cancer is missing, as is a comprehensive analysis of the clinical significance of SLFN11 as a predictive biomarker to DDA and/or DNA damage-response inhibitor (DDRi) therapies.

Methods

We used a multidisciplinary effort combining specific immunohistochemistry, pharmacology tests, anticancer combination therapies and mechanistic studies to assess SLFN11 as a potential biomarker for stratification of patients treated with several DDA and/or DDRi in the preclinical and clinical setting.

Results

SLFN11 protein associated with both preclinical and patient treatment response to DDA, but not

SUBMITTER: Winkler C 

PROVIDER: S-EPMC7921667 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature